Blood Product Ratios in Children with Nontraumatic Life-Threatening Bleeding
Monday, April 25, 2022
9:15 AM – 9:30 AM US MT
Location: Convention Center: 705/707
CE: Enduring CME: 0.25
Publication Number: 3085.6
Callie Marshall, Washington University in St. Louis School of Medicine, Maplewood, MO, United States; Philip C. Spinella, University of Pittsburgh School of Medicine, SEWICKLEY, PA, United States; Cassandra Josephson, Emory University School of Medicine, Atlanta, GA, United States
Presenting Author(s)
Callie Marshall, MD, MPH
Resident Physician Washington University in St. Louis School of Medicine Maplewood, Missouri, United States
Participants should be aware of the following financial/non-financial relationships:
Callie Marshall, MD, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Philip C. Spinella, Spinella, MD: ● Cerus (Currently Ongoing) (Products/Services: Consultant). ● Haima (Currently Ongoing) (Products/Services: Advisory Committee, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds). ● Hemanext (Currently Ongoing) (Products/Services: Advisory Committee). ● Kalocyte (Currently Ongoing) (Products/Services: Intellectual Property including patent beneficiary and royalties, Board Member or Executive Role, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds). ● Secure Transfusion Services (Currently Ongoing) (Products/Services: Consultant).
Cassandra Josephson, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.